On January 9, 2025, Genenta Science formally announced the strengthening of its partnership with AGC Biologics through an amended Development and Master Services Agreement. This agreement secures an exclusive GMP suite at AGC Biologics' Milan facility, dedicated to the manufacturing of Genenta’s cell therapy product.
This strategic enhancement to manufacturing capabilities is expected to improve efficiency and reliability in Genenta's production processes. The company projects manufacturing 27 autologous drug products in 2025 to support its ongoing clinical trials.
The strengthened partnership is crucial for Genenta's commitment to patients participating in its Glioblastoma Multiforme (GBM) and metastatic Renal Cell Carcinoma (mRCC) trials. This increased capacity ensures the ability to treat a larger number of patients and further validate its therapeutic approach.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.